

ABSTRACT OF THE DISCLOSURE

5 The present invention provides compounds which have a
pyrazinone or pyridinone ring at P3 and an optionally substituted
heteroaryl group at P1. These compounds have biological activity
as active and potent inhibitors of thrombin. Their
pharmaceutically acceptable salts, pharmaceutical compositions
10 thereof and methods of using these compounds and pharmaceutical
compositions comprising these compounds as therapeutic agents for
treatment of disease states in mammals which are characterized by
abnormal thrombosis are also described.